Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
 |
Männedorf, Switzerland, June 19, 2012 – Tecan’s Infinite® 200 series microplate readers have proved to be a valuable asset for the Experimental Nephrology laboratory an the University Hospital of Münster, aiding the development of both cell-based and ex vivo fluorescence techniques for the investigation of cell membrane transport in the proximal tubules of the kidney. Svenja Holle, who recently won the 2011 Tecan Award for her work on this innovative optical method, explained: “Organic cation transporters (OCTs) in the basolateral membrane of proximal tubules play an important role in the nephrotoxic effects of many drugs, and so our group has been investigating how these transporters are regulated to develop potential strategies to prevent the harmful side effects of these drugs.”
“We initially developed a cell-based technique using an inverted microscope to follow uptake of the fluorescent marker ASP+, and were able to convert this to a high throughput microplate format using the flexibility of Tecan’s Infinite M200 reader. To further improve the biological relevance of results, we have now adapted this technique to a true ex vivo method using Infinite 200 series readers, allowing us to analyze the behavior of OCTs in proximal tubules isolated directly from the kidney. This offers a huge increase in throughput compared with inverted microscopy, as well as increasing the number of assays which can be performed with a given amount of starting material, significantly reducing the cost per assay.”
To find out more about Tecan’s Infinite 200 PRO series, visit www.tecan.com/infinite200
For more information please contact
Tecan Trading AG
Cornelia Kegele, Antonietta Allocca
Seestrasse 103
CH-8708 Männedorf
Tel +41 (0)44 922 81 11
Fax +41 (0)44 922 81 12
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).